Icatibant Injection
Product Images NDC 69097-664

Product Visual Gallery

This gallery contains 22 technical images submitted to the FDA as part of the official labeling for Icatibant (NDC 69097-664). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Cipla Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

38971837 750d 4016 Bc05 618d00dacf0d 01

Chemical structure of Icatibant, as shown in the image, depicting the molecular arrangement of atoms for this active pharmaceutical ingredient.*

FDA Label Image

38971837 750d 4016 Bc05 618d00dacf0d 02

A Kaplan-Meier curve depicting the proportion of patients not achieving a 50% reduction in symptoms over time (hours) following a dose. Two groups are shown: Icatibant injection (N=43) and placebo (N=45). The graph illustrates symptom reduction progression up to 60 hours post-dose.*

FDA Label Image

38971837 750d 4016 Bc05 618d00dacf0d 03

An instructional diagram illustrating components of the ICATIBANT injection kit, including a prefilled syringe with labeled plunger, syringe barrel, and protective cap over the syringe tip. It also shows a capped needle with a needle cap and needle cap seal, and an alcohol wipe packet labeled as "wipe not included."*

FDA Label Image

38971837 750d 4016 Bc05 618d00dacf0d 04

An instructional illustration showing hands sliding open a box containing Icatibant Injection 30 mg/3 mL (10 mg/mL) by Cipla USA Inc. The image demonstrates how to open the packaging to access the injection device inside, intended for subcutaneous use.*

FDA Label Image

38971837 750d 4016 Bc05 618d00dacf0d 05

An instructional illustration showing two hands manipulating a vial and a syringe, depicting the preparation or drawing of medication for injection. The image suggests steps for handling the injection product but contains no text or labeling.*

FDA Label Image

38971837 750d 4016 Bc05 618d00dacf0d 06

An instructional illustration showing two hands preparing a subcutaneous injection with a syringe and a vial. One hand is holding the vial upside down, while the other hand is withdrawing the medication into the syringe. The image is related to the administration of ICATIBANT 30 mg/3 mL injection by Cipla USA Inc.*

FDA Label Image

38971837 750d 4016 Bc05 618d00dacf0d 07

An instructional illustration showing a hand holding a syringe with the other hand twisting or removing a cap or protective cover from the syringe tip, likely demonstrating preparation for injection.*

FDA Label Image

38971837 750d 4016 Bc05 618d00dacf0d 08

An instructional diagram showing the location for subcutaneous injection on the lower back on both sides of the spine. No text or other markings are present in the illustration.*

FDA Label Image

38971837 750d 4016 Bc05 618d00dacf0d 09

An instructional line drawing showing the administration of a subcutaneous injection into the abdomen. A hand is depicted holding a syringe at an angle, targeting the skin of the lower abdominal area, demonstrating the proper injection technique for subcutaneous administration.*

FDA Label Image

38971837 750d 4016 Bc05 618d00dacf0d 10

An instructional illustration showing a hand holding a vial while another hand uses a syringe to withdraw liquid from the vial. An arrow indicates the direction of the syringe pulling the liquid from the vial. This image relates to the subcutaneous injection preparation process.*

FDA Label Image

38971837 750d 4016 Bc05 618d00dacf0d 11

An instructional illustration showing a hand holding a syringe, positioned to administer an injection. The syringe is shown with a needle attached, oriented for subcutaneous injection.*

FDA Label Image

38971837 750d 4016 Bc05 618d00dacf0d 12

An instructional line drawing illustrating a hand administering a subcutaneous injection to the abdomen area, showing the injection technique relevant to subcutaneous drug delivery.*

FDA Label Image

38971837 750d 4016 Bc05 618d00dacf0d 13

An instructional illustration showing two hand positions for subcutaneous injection angles. The left image depicts a 45-degree injection angle with the syringe held in one hand and the other hand lifting the skin. The right image shows a 90-degree injection angle with the syringe held perpendicularly to the skin.*

FDA Label Image

38971837 750d 4016 Bc05 618d00dacf0d 14

An instructional illustration showing a person administering a subcutaneous injection in the abdominal area. The image depicts one hand pinching the skin while the other hand holds the syringe at an angle for injection.*

FDA Label Image

38971837 750d 4016 Bc05 618d00dacf0d 15

Illustration showing the subcutaneous injection technique where a syringe is administered into the abdominal area, demonstrating proper use for a subcutaneous injection.*

FDA Label Image

38971837 750d 4016 Bc05 618d00dacf0d 16

An instructional illustration showing a hand administering a subcutaneous injection into the abdomen, with an arrow indicating the direction of injection. This image is related to the subcutaneous injection route of the medication.*

FDA Label Image

38971837 750d 4016 Bc05 618d00dacf0d 17

An instructional diagram showing a hand holding a syringe being inserted into a biohazard container labeled with "BIOHAZARD" and "DO NOT RECYCLE CONTAINS SHARPS." Another hand is depicted pressing the lid to close the container securely. The illustration demonstrates proper disposal of sharps after injection use.*

FDA Label Image

38971837 750d 4016 Bc05 618d00dacf0d 18

Label for Icatibant Injection 30 mg/3 mL (10 mg/mL) in a prefilled syringe for subcutaneous use. The label indicates manufacturing by Cipla Ltd., India, for Cipla USA Inc., Warren, NJ. It includes the NDC 69097-664, barcode, and a designated area for lot and expiration date printing.*

FDA Label Image

38971837 750d 4016 Bc05 618d00dacf0d 19

Label for Icatibant Injection 30 mg/3 mL (10 mg/mL) in a prefilled syringe for subcutaneous use. Manufactured by Cipla Ltd., India, for Cipla USA Inc., Warren, NJ. The label includes the NDC 69097-664-68 and space for LOT and EXP dates, with a barcode present.*

FDA Label Image

38971837 750d 4016 Bc05 618d00dacf0d 20

The label for Icatibant Injection 30 mg/3 mL (10 mg/mL) by Cipla USA Inc. Features details for a single-dose, subcutaneous injection in a 3 mL prefilled syringe. The label includes dosage strength, route of administration, NDC number 69097-664, manufacturer information, and storage instructions. It indicates Rx only and contains barcodes and regulatory text.*

FDA Label Image

38971837 750d 4016 Bc05 618d00dacf0d 21

The packaging label for Icatibant Injection displays a 30 mg/3 mL (10 mg/mL) subcutaneous injection. It states the product is a single-dose prefilled syringe supplied by Cipla USA Inc. The label includes storage instructions, a barcode, inactive ingredient information, and manufacturer details from Cipla Ltd., India. The label prominently features the product name and dosage strength multiple times on a white background with blue and black text.*

FDA Label Image

38971837 750d 4016 Bc05 618d00dacf0d 22

Label for Icatibant Injection 30 mg/3 mL (10 mg/mL) prefilled syringe by Cipla USA Inc. The label indicates the product is for subcutaneous use only and each syringe delivers 30 mg icatibant equivalent to 34.14 mg icatibant acetate. The label includes NDC 69097-664, product branding, dosing strength, manufacturer information, and a barcode. The package contains three 3 mL prefilled syringes.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.